Related Experiment Video

Updated: Feb 3, 2026

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.9K

Application of G-CSF in Congestive Heart Failure Treatment

Atena Pourtaji1, Vajiheh Jahani2, Seyed Mohammad Hassan Moallem3

  • 1Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Current Cardiology Reviews
|November 1, 2018
PubMed

Insights

Granulocyte Colony-Stimulating Factor (G-CSF) shows promise for treating congestive heart failure (CHF). G-CSF aids cardiac repair and prevents adverse remodeling, offering a novel therapeutic avenue for heart failure patients.

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Pharmacology

Background:

  • Congestive Heart Failure (CHF) involves the heart's inability to pump sufficient blood, leading to cardiac remodeling.
  • Cardiac myocytes can proliferate post-myocardial infarction (MI), suggesting regeneration and neovascularization as therapeutic targets.
  • Granulocyte Colony-Stimulating Factor (G-CSF) is a cytokine known for neutrophil development and cardiac repair post-MI.

Purpose of the Study:

  • To review the potential of G-CSF as a novel treatment for congestive heart failure.
  • To explore G-CSF's mechanisms in preventing cardiac remodeling and promoting repair.
  • To evaluate G-CSF's efficacy for clinical application in CHF therapy.

Main Methods:

  • Literature search of PubMed and other databases (2003-2017).
  • Keywords included "G-CSF", "congestive heart failure", "new therapies for CHF", "filgrastim", and "in vivo study".

Main Results:

  • G-CSF promotes cardiac repair via stem cell mobilization.
  • G-CSF directly stimulates angiogenesis, contributing to heart repair.
  • These mechanisms collectively enhance cardiac cell repair and function.

Conclusions:

  • G-CSF presents a promising therapeutic target for CHF.
  • It effectively prevents cardiac remodeling and promotes repair through multiple mechanisms.
  • G-CSF's efficacy supports its potential use in clinical practice for heart failure.
Abstract

Keywords:
G-CSFIn vivo studycongestive heart failurefilgrastimnew therapies for CHFprevention.

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.4K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319